Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.

摘要: The newer atypical antipsychotic agents (AAPs) represent an attractive therapeutic option for a wide range of psychotic disorders, including schizophrenia and bipolar mania, because the reduced risk disabling extrapyramidal symptoms. However, their growing use has raised questions about tolerability over endocrine, metabolic, cardiovascular axes. Indeed, drugs are associated, to differing extents, with mild elevation aminotransferases related weight gain, AAP-induced metabolic syndrome, nonalcoholic fatty liver disease. Although hepatic safety new AAPs seems improved that chlorpromazine, they can occasionally cause idiosyncratic injury varying phenotypes and, rarely, lead acute failure. group heterogeneous, chemically unrelated compounds distinct pharmacological pharmacokinetic properties substantially different profiles, which precludes notion class effect hepatotoxicity highlights need individualized approach. We discuss current evidence on potential AAPs, emerging underlying mechanisms, limitations inherent this both establishing proper causality assessment developing strategies management.